Skip to search formSkip to main contentSkip to account menu

TZT 1027

Known as: TZT-1027, TZT1027 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

soblidotin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer
PurposeThe purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the… 
2007
2007
Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents
TZT-1027 (Soblidotin), a microtubule-depolymerizing agent exerts both a direct cytotoxic activity against cancer cells and an… 
Highly Cited
2006
Highly Cited
2006
Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy
TZT‐1027, a novel chemotherapeutic agent, is derived from dolastatin 10, and blocks cells during G2/M‐phase by interfering with… 
2006
2006
Antitumor activity of TZT-1027 (Soblidotin).
BACKGROUND TZT-1027 (Soblidotin), a newly synthesized dolastatin 10 derivative that depolymerizes microtubules, has potent… 
2006
2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
BACKGROUND TZT-1027 is a tubulin-binding drug and synthetic derivative of dolastatin-10 with cytotoxic and antivascular activity… 
2005
2005
Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors
Purpose: TZT-1027 {N2-(N,N-dimethyl-l-valyl)-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl… 
2001
2001
Association of p53 gene mutations with sensitivity to TZT‐1027 in patients with clinical lung and renal carcinoma
It has been revealed that chemotherapy using DNA‐damaging agents and radiotherapy were influenced by the p53 status of tumors… 
2001
2001
Enhanced antitumor activities of TZT-1027 against TNF-α or IL-6 secreting Lewis lung carcinoma in vivo
Abstract.Purpose: TZT-1027, an antimicrotubule agent that inhibits the polymerization of tubulin, shows potent antitumor activity… 
Highly Cited
2000
Highly Cited
2000
Characterization of the Interaction of TZT‐1027, a Potent Antitumor Agent, with Tubulin
TZT‐1027, a derivative of dolastatin 10 isolated from the Indian Ocean sea hare Dolabella auricularia in 1987 by Pettit et al… 
Highly Cited
1997
Highly Cited
1997
Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative
Dolastatin 10, a pentapeptide isolated from the marine mollusk Dolabella auricularia, has antitumor activity. TZT‐1027, a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)